Cargando…
Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S.
Non-cystic fibrosis bronchiectasis (NCFBE) is a rare, chronic lung disease characterized by bronchial inflammation and permanent airway dilation. Chronic infections with P. aeruginosa have been linked to higher morbidity and mortality. To understand the impact of P. aeruginosa in NCFBE on health car...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753649/ https://www.ncbi.nlm.nih.gov/pubmed/29099036 http://dx.doi.org/10.3390/medsci5040020 |
_version_ | 1783290311569571840 |
---|---|
author | Blanchette, Christopher M. Noone, Joshua M. Stone, Glenda Zacherle, Emily Patel, Ripsi P. Howden, Reuben Mapel, Douglas |
author_facet | Blanchette, Christopher M. Noone, Joshua M. Stone, Glenda Zacherle, Emily Patel, Ripsi P. Howden, Reuben Mapel, Douglas |
author_sort | Blanchette, Christopher M. |
collection | PubMed |
description | Non-cystic fibrosis bronchiectasis (NCFBE) is a rare, chronic lung disease characterized by bronchial inflammation and permanent airway dilation. Chronic infections with P. aeruginosa have been linked to higher morbidity and mortality. To understand the impact of P. aeruginosa in NCFBE on health care costs and burden, we assessed healthcare costs and utilization before and after P. aeruginosa diagnosis. Using data from 2007 to 2013 PharMetrics Plus administrative claims, we included patients with ≥2 claims for bronchiectasis and >1 claim for P. aeruginosa; then excluded those with a claim for cystic fibrosis. Patients were indexed at first claim for P. aeruginosa and were required to have >12 months before and after the index P. aeruginosa. The mean differences in utilization and costs were assessed using paired Student’s t-tests for statistical significance. Mean total healthcare costs per patient were $36,213 pre-P. aeruginosa diagnosis versus $67,764 post-P. aeruginosa, an increase of 87% (p < 0.0001). Inpatient costs represented the largest proportion of total healthcare costs post-P. aeruginosa (54%) with an increase of four hospitalizations per patient (p < 0.0001). NCFBE patients with evidence of P. aeruginosa incur substantially greater healthcare costs and utilization after P. aeruginosa diagnosis. Future research should explore methods of earlier identification of NCFBE patients with P. aeruginosa, as this may lead to fewer severe exacerbations, thereby resulting in a reduction in hospitalizations and healthcare costs. |
format | Online Article Text |
id | pubmed-5753649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-57536492018-01-08 Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S. Blanchette, Christopher M. Noone, Joshua M. Stone, Glenda Zacherle, Emily Patel, Ripsi P. Howden, Reuben Mapel, Douglas Med Sci (Basel) Article Non-cystic fibrosis bronchiectasis (NCFBE) is a rare, chronic lung disease characterized by bronchial inflammation and permanent airway dilation. Chronic infections with P. aeruginosa have been linked to higher morbidity and mortality. To understand the impact of P. aeruginosa in NCFBE on health care costs and burden, we assessed healthcare costs and utilization before and after P. aeruginosa diagnosis. Using data from 2007 to 2013 PharMetrics Plus administrative claims, we included patients with ≥2 claims for bronchiectasis and >1 claim for P. aeruginosa; then excluded those with a claim for cystic fibrosis. Patients were indexed at first claim for P. aeruginosa and were required to have >12 months before and after the index P. aeruginosa. The mean differences in utilization and costs were assessed using paired Student’s t-tests for statistical significance. Mean total healthcare costs per patient were $36,213 pre-P. aeruginosa diagnosis versus $67,764 post-P. aeruginosa, an increase of 87% (p < 0.0001). Inpatient costs represented the largest proportion of total healthcare costs post-P. aeruginosa (54%) with an increase of four hospitalizations per patient (p < 0.0001). NCFBE patients with evidence of P. aeruginosa incur substantially greater healthcare costs and utilization after P. aeruginosa diagnosis. Future research should explore methods of earlier identification of NCFBE patients with P. aeruginosa, as this may lead to fewer severe exacerbations, thereby resulting in a reduction in hospitalizations and healthcare costs. MDPI 2017-09-23 /pmc/articles/PMC5753649/ /pubmed/29099036 http://dx.doi.org/10.3390/medsci5040020 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Blanchette, Christopher M. Noone, Joshua M. Stone, Glenda Zacherle, Emily Patel, Ripsi P. Howden, Reuben Mapel, Douglas Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S. |
title | Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S. |
title_full | Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S. |
title_fullStr | Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S. |
title_full_unstemmed | Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S. |
title_short | Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S. |
title_sort | healthcare cost and utilization before and after diagnosis of pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the u.s. |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753649/ https://www.ncbi.nlm.nih.gov/pubmed/29099036 http://dx.doi.org/10.3390/medsci5040020 |
work_keys_str_mv | AT blanchettechristopherm healthcarecostandutilizationbeforeandafterdiagnosisofpseudomonasaeruginosaamongpatientswithnoncysticfibrosisbronchiectasisintheus AT noonejoshuam healthcarecostandutilizationbeforeandafterdiagnosisofpseudomonasaeruginosaamongpatientswithnoncysticfibrosisbronchiectasisintheus AT stoneglenda healthcarecostandutilizationbeforeandafterdiagnosisofpseudomonasaeruginosaamongpatientswithnoncysticfibrosisbronchiectasisintheus AT zacherleemily healthcarecostandutilizationbeforeandafterdiagnosisofpseudomonasaeruginosaamongpatientswithnoncysticfibrosisbronchiectasisintheus AT patelripsip healthcarecostandutilizationbeforeandafterdiagnosisofpseudomonasaeruginosaamongpatientswithnoncysticfibrosisbronchiectasisintheus AT howdenreuben healthcarecostandutilizationbeforeandafterdiagnosisofpseudomonasaeruginosaamongpatientswithnoncysticfibrosisbronchiectasisintheus AT mapeldouglas healthcarecostandutilizationbeforeandafterdiagnosisofpseudomonasaeruginosaamongpatientswithnoncysticfibrosisbronchiectasisintheus |